End points in pulmonary arterial hypertension: the way forward

The European Respiratory Journal
Andrew PeacockJ T Reeves

Abstract

Pulmonary arterial hypertension is a rare disease of poor prognosis. Despite its rarity >1,000 patients have been randomised in placebo-controlled trials using novel therapies, including prostacyclin analogues, endothelin receptor antagonists and, most recently, phosphodiesterase 5 inhibitors. Nearly all of these trials have used exercise capacity, measured by the unencouraged 6-min walking distance, as the primary end point and a variety of other measurements as secondary end points. This approach has been productive, leading to the licensing of a number of effective treatments. Future clinical trials, however, will probably assess drug combinations, make comparisons between drugs and include less severely ill patients. It is, therefore, timely to examine the end points used. The authors discussed the various end points that have been used in the past and possible end points that might be used in the future. End points considered included measurements of: exercise capacity, haemodynamics, quality of life, imaging of the right heart and circulation, and chemical markers of pulmonary hypertension. Many of these show promise but will have to be used in parallel and compared with conventional end points such as the 6-min walking d...Continue Reading

Citations

Feb 18, 2010·Annals of Biomedical Engineering·Rebecca R VanderpoolNaomi C Chesler
Jun 9, 2009·Internal and Emergency Medicine·Sheng Chin WuMaria Beatrice Secchi
Sep 22, 2007·International Journal of Clinical Practice. Supplement·L E R McLure, A J Peacock
Jul 28, 2009·International Journal of Clinical Practice. Supplement·S Gaine, M Gomberg-Maitland
Jul 29, 2004·American Journal of Respiratory and Critical Care Medicine·Peter M A Calverley
Aug 1, 2014·Annals of Thoracic Medicine·Majdy M IdreesRober D Levy
Jun 23, 2005·Current Medical Research and Opinion·Rogerio SouzaHumberto Bogossian
Aug 7, 2013·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·João Silva MarquesAntónio Nunes Diogo
Mar 7, 2007·Clinics in Chest Medicine·Jennifer L Snow, Steven M Kawut
Dec 23, 2009·Journal of Magnetic Resonance Imaging : JMRI·William M BradlowRaad H Mohiaddin
Jan 12, 2005·The American Journal of Cardiology·Steven M KawutRobyn J Barst
Jan 16, 2007·Respiratory Medicine·S A van WolferenA Vonk Noordegraaf
May 11, 2013·Pulmonary Circulation·Paul M HassounRonald J Oudiz
Oct 27, 2004·Current Opinion in Cardiology·Nazzareno GalièAngelo Branzi
Nov 4, 2009·Expert Review of Respiratory Medicine·Paul M Hassoun
May 19, 2010·Expert Review of Respiratory Medicine·Cecile Tissot, Maurice Beghetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
Anne KeoghTrevor J Williams
The European Respiratory Journal
Steven M Kawut, Harold I Palevsky
© 2022 Meta ULC. All rights reserved